Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

Emory University

Status and phase

Completed

Phase 1

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Treatments

Behavioral: Psychotherapy

Drug: Psilocybin

Other: Questionnaire Administration

Other: Quality-of-Life Assessment

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT05506982

P30CA138292 (U.S. NIH Grant/Contract)

EU5206-20 (Other Identifier)

STUDY00001905 (Other Identifier)

NCI-2020-13913 (Registry Identifier)

Details and patient eligibility

About

This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, and existential distress. Psilocybin psychotherapy, together with multidisciplinary palliative and supportive care, may help treat the anxiety, depression, and chronic pain felt by cancer survivors - defined here as cancer patients from time of diagnosis through the end-of-life.

Full description

PRIMARY OBJECTIVE:

I. To determine the safety, feasibility, and acceptability of a single administration of 25 mg psilocybin (psilocybin) provided under supportive conditions with multidisciplinary palliative care support (P-PC) in adult cancer survivors living with concurrent demoralization and chronic pain.

EXPLORATORY OBJECTIVE:

I. To evaluate for changes in demoralization, anxiety, depression, quality of life, pain, other symptoms, mysticism, awe, post-traumatic growth, social isolation, and psychosocial functioning from baseline to end-of-treatment to 3.5-month follow up.

OUTLINE:

Patients receive psilocybin orally (PO) and undergo observation for up to 8 hours on day 14.

After completion of study intervention, patients are followed up on days 15, 21, 42, 56, and 98.

Enrollment

11 patients

Sex

All

Ages

26+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed informed consent form (ICF)
Diagnosis of solid or liquid cancer made >= 1 year at any stage in cancer survivorship (specifically, active cancer treatment or no cancer-directed therapy either in clinical remission or with advanced disease)
Prognosis of greater than six months as determined by their primary oncologist
Moderate-to-severe demoralization (score of >= 10 on the Demoralization Scale-II [DS-II])
Chronic pain (pain lasting > 3 months) per patient report and score of >= 5 for average pain level on Brief Pain Inventory
Age >= 26 years old and ≤85 years old
Availability of a friend or family member into whose care the participant can be released following the drug administration session

Exclusion criteria

Pregnancy or breastfeeding
Women of childbearing potential (i.e., not permanently sterilized, not postmenopausal) who decline to use a highly effective dual contraceptive method for the duration of the study. Dual contraceptive method use is defined by a use a barrier contraceptive in addition to another method to prevent pregnancy, including sterilization, hormonal methods, intrauterine devices, and hormonal pills.
Age < 26 years old and > 85 years old
Poor functional status (Eastern Cooperative Oncology Group [ECOG] score of >= 2)
Major cognitive impairment as determined by principal investigator
Non-fluency in the English language
Personal history of a psychotic disorder or Bipolar disorder type I/II
Active suicidal ideation with intent in the last 3 months (Columbia Suicide Severity Rating Scale suicidal ideation score > 3) or any suicide attempt in the past year
Current substance use disorder (i.e., present in last six months), of greater than mild severity as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-V)
History of a seizure disorder in adulthood
Active central nervous system (CNS) metastases or symptomatic CNS infection
Uncontrolled hypertension (mean blood pressure (mmHg) exceeding 139 systolic and 89 diastolic) and heart rate exceeding 90 beats per minute
Clinically significant cardiovascular disease (coronary artery disease, congestive heart failure, arrhythmia, or QTc>450ms)
Supplemental oxygen requirement
Body mass index =< 18
Renal insufficiency as evidenced by creatinine clearance (CrCl) < 30 mL/min
Concomitant use of drugs known to interact with psilocybin (probenecid, diclofenac)
Consistent use of serotonergic drugs including selective serotonin reuptake inhibitors (SSRIs), serotoninnorepinephrine reuptake inhibitors (SNRIs), or efavirenz, as well as monoamine oxidase inhibitors (MAOIs). Subjects using any other antidepressant, stimulant, or antipsychotic medications on Day 0 (baseline visit) may be allowed to enroll in the study if they elect to taper off the medications under medical supervision by the PI and the study psycho-oncologist (PO) by the day prior to the baseline visit
Considered by the principal investigator to be inappropriate for the study due to safety concerns or to be unlikely to complete the protocol